NYLIM
JAZZ icon

New York Life Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

New York Life Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,987
Closed -$789K – 817
2025
Q3 		$789K Sell
5,987
-216
-3% -$25.9K 0.01% 705
2025
Q2 		$658K Sell
6,203
-114
-2% -$12.4K 0.01% 725
2025
Q1 		$784K Sell
6,317
-75
-1% -$9.78K 0.01% 697
2024
Q4 		$787K Sell
6,392
-625
-9% -$73.7K 0.01% 712
2024
Q3 		$782K Sell
7,017
-403
-5% -$44.2K 0.01% 744
2024
Q2 		$792K Buy
7,420
+469
+7% +$51.6K 0.01% 732
2024
Q1 		$837K Sell
6,951
-163
-2% -$20K 0.01% 719
2023
Q4 		$875K Sell
7,114
-152
-2% -$19K 0.01% 691
2023
Q3 		$941K Buy
7,266
+3,628
+100% +$483K 0.01% 637
2023
Q2 		$451K Buy
3,638
+1,970
+118% +$265K ﹤0.01% 807
2023
Q1 		$244K Buy
1,668
+41
+3% +$6.07K ﹤0.01% 1179
2022
Q4 		$259K Buy
+1,627
New +$238K ﹤0.01% 1144

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

New York Life Investment Management's JAZZ Position: Q4 2025 in Review

New York Life Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 5,987 shares — an estimated $789K sold.

New York Life Investment Management first reported a position in JAZZ in Q4 2022 and held it in 12 quarters. The position peaked at $941K in Q3 2023. 574 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • New York Life Investment Management reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • New York Life Investment Management sold 5,987 Jazz Pharmaceuticals shares in Q4 2025, an estimated $789K.
  • New York Life Investment Management first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 12 quarters.
  • New York Life Investment Management's Jazz Pharmaceuticals position peaked at $941K in Q3 2023.
  • 574 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on New York Life Investment Management's 13F filing for Q4 2025, filed 5 Feb 2026.